Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience...
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience...
Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosisDenali to...
TOKYO and CAMBRIDGE, United Kingdom, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world...
-- Q4 2022 revenue projected to range from $275,000 to $285,000 ---- Full year 2022 revenue projected to range from...
TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is...
Figure Initial treatment imaging from first patient treated in the ReSPECT-GBM Phase 2b trialAUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE)...
CINCINNATI, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a...
Record revenue of approximately $2.5 million for the three months ended December 31, 2022 and $8.5 million for full-year 2022Revenue...
SAN FRANCISCO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Adaptive Research, an integrated clinical trial site organization with a unique purpose...
-- Fifth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’...
BEDFORD, Mass., and SHANGHAI, China, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks...
DENVER, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment OptionsNEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ovid...
REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl...
New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to DoorstepsNEWTOWN, Pa., Jan. 03, 2023 (GLOBE NEWSWIRE) --...
LONDON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS...
Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet needLONDON, Dec. 27, 2022...
SAB brings extensive expertise in precision oncology, drug development, and early phase clinical trialsNEW HAVEN, Conn., Dec. 13, 2022 (GLOBE...
ROCKAWAY, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that...
Parkinson’s disease (PD) patients treated with NE3107 for 28 days experienced a clinically meaningful increase in motor control.Additional data presented...